BACKGROUND: Long-term data of ciclosporin A (CsA) treatment in daily practice in patients with severe atopic dermatitis (AD) are lacking. OBJECTIVES: To perform a detailed analysis of drug survival, which is the length of time a patient continues to take a drug, for CsA in a long-term daily practice cohort of patients with AD. The secondary objective was to identify determinants of drug survival. METHODS: Data were extracted from a retrospective cohort of patients treated with CsA for AD. Drug survival was analysed using Kaplan-Meier survival curves. Determinants of drug survival were analysed using uni- and multivariate Cox regression analyses with backward selection. RESULTS: In total, 356 adult patients were analysed (386 patient-years). The overall drug survival rates were 34%, 18%, 12% and 4% after 1, 2, 3 and 6 years, respectively. Reasons for discontinuation were controlled AD (26·4%), side-effects (22·2%), ineffectiveness (16·3%), side-effects plus ineffectiveness (6·2%) or other reasons (11·0%). Older age was associated with a decreased drug survival related to controlled AD [hazard ratio (HR) 0·91]. Older age was also associated with a decreased drug survival related to side-effects (HR 1·14). An intermediate-to-high starting dose (> 3·5-5·0 mg kg(-1) daily) was associated with an increased drug survival related to ineffectiveness (HR 0·63). CONCLUSIONS: This is the first study on drug survival for CsA treatment in AD. Older age was associated with decreased drug survival related to controlled AD and side-effects. An intermediate-to-high starting dose was associated with an increased drug survival related to ineffectiveness.
BACKGROUND: Long-term data of ciclosporin A (CsA) treatment in daily practice in patients with severe atopic dermatitis (AD) are lacking. OBJECTIVES: To perform a detailed analysis of drug survival, which is the length of time a patient continues to take a drug, for CsA in a long-term daily practice cohort of patients with AD. The secondary objective was to identify determinants of drug survival. METHODS: Data were extracted from a retrospective cohort of patients treated with CsA for AD. Drug survival was analysed using Kaplan-Meier survival curves. Determinants of drug survival were analysed using uni- and multivariate Cox regression analyses with backward selection. RESULTS: In total, 356 adult patients were analysed (386 patient-years). The overall drug survival rates were 34%, 18%, 12% and 4% after 1, 2, 3 and 6 years, respectively. Reasons for discontinuation were controlled AD (26·4%), side-effects (22·2%), ineffectiveness (16·3%), side-effects plus ineffectiveness (6·2%) or other reasons (11·0%). Older age was associated with a decreased drug survival related to controlled AD [hazard ratio (HR) 0·91]. Older age was also associated with a decreased drug survival related to side-effects (HR 1·14). An intermediate-to-high starting dose (> 3·5-5·0 mg kg(-1) daily) was associated with an increased drug survival related to ineffectiveness (HR 0·63). CONCLUSIONS: This is the first study on drug survival for CsA treatment in AD. Older age was associated with decreased drug survival related to controlled AD and side-effects. An intermediate-to-high starting dose was associated with an increased drug survival related to ineffectiveness.
Authors: E Haufe; S Abraham; A Heratizadeh; I Harder; A Zink; E Weisshaar; A Kleinheinz; R von Kiedrowski; M Worm; M Bell; A Wollenberg; K Neubert; P Staubach-Renz; M Hilgers; T Bieber; I Fell; B Homey; I Effendy; M Mempel; K Schäkel; S Beissert; S Weidinger; T Werfel; J Schmitt Journal: Hautarzt Date: 2018-10 Impact factor: 0.751
Authors: Lieneke F M Ariëns; Daphne S Bakker; Jorien van der Schaft; Floor M Garritsen; Judith L Thijs; Marjolein S de Bruin-Weller Journal: Ther Adv Chronic Dis Date: 2018-05-11 Impact factor: 5.091
Authors: Louise A A Gerbens; Aaron E Boyce; Dmitri Wall; Sebastien Barbarot; Richard J de Booij; Mette Deleuran; Maritza A Middelkamp-Hup; Amanda Roberts; Christian Vestergaard; Stephan Weidinger; Christian J Apfelbacher; Alan D Irvine; Jochen Schmitt; Paula R Williamson; Phyllis I Spuls; Carsten Flohr Journal: Trials Date: 2017-02-27 Impact factor: 2.279
Authors: Lotte S Spekhorst; Lieneke F M Ariëns; Jorien van der Schaft; Daphne S Bakker; Marijke Kamsteeg; Albert J Oosting; Ilona de Ridder; Annemiek Sloeserwij; Geertruida L E Romeijn; Marlies de Graaf; Inge Haeck; Judith L Thijs; Marie L A Schuttelaar; Marjolein S de Bruin-Weller Journal: Allergy Date: 2020-05-05 Impact factor: 13.146
Authors: Stine Elsgaard; Anna Kathrine Danielsen; Jacob P Thyssen; Mette Deleuran; Christian Vestergaard Journal: Int J Womens Dermatol Date: 2021-07-22
Authors: F M Vermeulen; L A A Gerbens; J Schmitt; M Deleuran; A D Irvine; K Logan; W Ouwerkerk; C Vestergaard; C Flohr; P I Spuls Journal: Br J Dermatol Date: 2020-03-18 Impact factor: 9.302
Authors: Servando E Marron; Lucia Tomas-Aragones; Carlos A Moncin-Torres; Manuel Gomez-Barrera; Francisco Javier Garcia-Latasa de Aranibar Journal: Life (Basel) Date: 2021-06-25